Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pevonedistat plus azacitidine vs azacitidine in higher-risk MDS/CMML or low-blast AML
CTR20192035Phase 3Terminated
- Sponsor
- Takeda
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pevonedistat in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), acute myeloid leukemia (AML), sponsored by Takeda. Started Oct 2019; status: terminated.
02
Drugs
pevonedistat
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on CTR20192035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192035.